Skip to main content
*** NOTE: Terms of Service Updated 21 Feb 2018 ***

FDA Approval of First Drug to Treat Tuberous Sclerosis Complex

  • Published: 2010-10-30 (Revised/Updated 2017-06-26) : Tuberous Sclerosis Alliance.
  • Synopsis: Tuberous Sclerosis Alliance Announces FDA Approval of First Drug to Treat Tuberous Sclerosis Complex.
Tuberous Sclerosis

Tuberous sclerosis (tuberous sclerosis complex (TSC)) is a rare multi-system genetic disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys, heart, eyes, lungs, and skin. A combination of symptoms may include seizures, intellectual disability, developmental delay, behavioral problems, skin abnormalities, lung and kidney disease. Some people with tuberous sclerosis have such mild signs and symptoms that the condition isn't diagnosed until adulthood, or it goes undiagnosed. Others experience serious disabilities.

Main Document

Quote: "People with TSC commonly have epilepsy, behavioral disorders (such as attention deficit disorder-ADD), skin disorders (such as lesions) and other symptoms."

Tuberous Sclerosis Alliance Announces FDA Approval of First Drug to Treat Tuberous Sclerosis Complex.

The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA).

This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.

This type of tumor develops in approximately 15-20 percent of individuals with TSC, and typically becomes symptomatic in children and adolescents, and rarely in adults.

"SEGAs can be challenging for individuals with tuberous sclerosis complex and for the whole family, which is why we are encouraged to see ongoing research and new treatment options for these individuals," said Vicky Whittemore, Ph.D., TS Alliance Vice President and Chief Scientific Officer.

"Prior to Afinitor the only treatment option for individuals with growing SEGAs, many of them children, was brain surgery."

"At the TS Alliance, it's crucial for us to raise awareness about the tuberous sclerosis complex, as many individuals go undiagnosed or even misdiagnosed," explained Kari Luther Rosbeck, President and Chief Executive Officer for the TS Alliance.

"Therefore, it's important that anyone with TSC get the care needed by having multiple treatment options available."

"TSC research has moved from the identification of the genes for TSC in the 1990s to clinical trials in recent years, and the development of new treatment options for all of the symptoms of TSC is our priority," Whittemore continued.

"This is the first treatment that has been approved by the FDA specifically for TSC, and Afinitor offers a new treatment option for individuals with the disease."

"Because identifying new treatments is so important, the TS Alliance instituted a new TSC Drug Screening Program in 2010, which will help drive and accelerate basic and translational research," Rosbeck said. According to Rosbeck, the program provides funding to test drugs that are already FDA-approved or new compounds in animal models of TSC in order to fast-track the translation of basic research to new treatments for patients.

"By bringing together biotech and pharmaceutical companies with researchers interested in TSC, our hope is that we can accelerate the testing of new treatments for TSC," added Dr. Whittemore.

The TS Alliance is the only national voluntary health organization dedicated to finding a cure for tuberous sclerosis complex (TSC) and improving the lives of those affected.

TSC is a multi-system genetic disorder affecting many parts of the body, primarily due to the growth of tumors in the vital organs, such as the brain, heart, kidneys, lungs, eyes and skin.

People with TSC commonly have epilepsy, behavioral disorders (such as attention deficit disorder-ADD), skin disorders (such as lesions) and other symptoms.

TSC is estimated to affect nearly 50,000 people in the U.S., and more than 1 million worldwide.

For more information about the TS Alliance or TSC, call (800) 225-6872 or visit www.tsalliance.org

Awareness: Tuberous Sclerosis Complex (TSC) Awareness

Blue awareness ribbonThe blue ribbon color shows support and awareness for Tuberous Sclerosis, and the month of May is International TSC Awareness Month, with TSC Awareness Day falling on May 15.

In the U.K. Tuberous Sclerosis Complex Awareness Month takes place each October. May 15th is TSC Global Awareness Day.

Statistics: Tuberous Sclerosis

Similar Topics

1 : Statement From FDA Commissioner on Steps to Facilitate Efficient Generic Drug Review to Enhance Competition, Promote Access and Lower Drug Prices : U.S. FDA.
2 : FDA Permits Marketing of Device to Treat Diabetic Foot Ulcers : U.S. Food and Drug Administration.
3 : U.S. FDA Approves Gene Therapy for Treatment of Cancer and Life-threatening Diseases : U.S. Food and Drug Administration.
4 : U.S. FDA Approves Radicava (Edaravone) to Treat ALS : U.S. Food and Drug Administration.
5 : U.S. FDA Approves Ocrevus (Ocrelizumab) to Treat Multiple Sclerosis : U.S. Food and Drug Administration (FDA).
From our FDA Approvals section - Full List (63 Items)

Submit disability news, coming events, as well as assistive technology product news and reviews.


Loan Information for low income singles, families, seniors and disabled. Includes home, vehicle and personal loans.


Famous People with Disabilities - Well known people with disabilities and conditions who contributed to society.


List of awareness ribbon colors and their meaning. Also see our calendar of awareness dates.


Blood Pressure Chart - What should your blood pressure be, and information on blood group types/compatibility.





1 : Free Eye Exams to Service and Working Animals in May from Veterinary Ophthalmologists
2 : Early Childhood Education Needs to be Accessible and Affordable
3 : How the Human Brain Can Tell Our Arms and Legs Apart
4 : Protein Levels in Spinal Fluid Correlate to Posture and Gait Difficulty in Parkinson's Disease

Citation


Disclaimer: This site does not employ and is not overseen by medical professionals. Content on Disabled World is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. See our Terms of Service for more information.

Reporting Errors: Disabled World is an independent website, your assistance in reporting outdated or inaccurate information is appreciated. If you find an error please let us know.